Oncomed Pharmaceuticals Inc (NASDAQ:OMED) shares saw strong trading volume on Friday . 3,356,692 shares were traded during trading, an increase of 602% from the previous session’s volume of 478,194 shares.The stock last traded at $0.99 and had previously closed at $0.83.

Several research analysts have recently weighed in on the company. Zacks Investment Research downgraded Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. ValuEngine raised Oncomed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Wells Fargo & Co reaffirmed a “market perform” rating and set a $1.50 target price (down from $8.00) on shares of Oncomed Pharmaceuticals in a research note on Thursday, December 6th.

The company has a market capitalization of $32.45 million, a price-to-earnings ratio of -6.19 and a beta of 1.81.

Several hedge funds have recently made changes to their positions in OMED. Birchview Capital LP raised its stake in shares of Oncomed Pharmaceuticals by 45.4% during the 4th quarter. Birchview Capital LP now owns 172,557 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 53,868 shares during the period. Geode Capital Management LLC raised its stake in shares of Oncomed Pharmaceuticals by 36.1% during the 4th quarter. Geode Capital Management LLC now owns 173,563 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 46,083 shares during the period. Norges Bank acquired a new position in Oncomed Pharmaceuticals in the 4th quarter valued at $136,000. Acadian Asset Management LLC raised its stake in Oncomed Pharmaceuticals by 26.1% in the 4th quarter. Acadian Asset Management LLC now owns 195,107 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 40,353 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Oncomed Pharmaceuticals in the 3rd quarter valued at $200,000. 44.76% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Oncomed Pharmaceuticals (OMED) Sees Strong Trading Volume” was first posted by Marea Informative and is the property of of Marea Informative. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.mareainformativa.com/news/2019/03/17/oncomed-pharmaceuticals-omed-sees-strong-trading-volume.html.

About Oncomed Pharmaceuticals (NASDAQ:OMED)

OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway.

See Also: Insider Trading

Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.